Mechanistic study of BNP7787-mediated cisplatin nephroprotection: Modulation of human aminopeptidase N

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 2, 2011, Pages 381-391

  Hausheer, F H ^a   Parker, A R ^a   Petluru, P N ^a   Jair, K W ^a   Chen, S ^a   Huang, Q ^a   Chen, X ^a   Ayala, P Y ^a   Shanmugarajah, D ^a   Kochat, H ^a  

^a BioNumerik Pharmaceuticals Inc   (United States)

Author keywords

Aminopeptidase N; BNP7787; Chemoprotective agent; Cisplatin; Dimesna; Mesna disulfide heteroconjugates; Nephrotoxicity; Nephrotoxigenic; Xenobiotic toxification pathway

Indexed keywords

CISPLATIN; CYSTEINYLGLYCINE; DIMESNA; GAMMA GLUTAMYLCYSTEINE; GLUTATHIONE; MICROSOMAL AMINOPEPTIDASE; 2,2' DITHIODIETHANESULFONIC ACID; 2,2'-DITHIODIETHANESULFONIC ACID; CYSTEINE; DIPEPTIDE; DRUG DERIVATIVE; GLYCINE; MESNA; PROTECTIVE AGENT; RECOMBINANT PROTEIN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; ENZYME KINETICS; ENZYME REGULATION; ENZYME SPECIFICITY; FLUOROMETRY; HUMAN; IN VITRO STUDY; METABOLITE; NEPHROTOXICITY; PRIORITY JOURNAL; RENAL PROTECTION; ALLOSTERISM; BIOCATALYSIS; BIOLOGICAL MODEL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; KIDNEY DISEASE; KINETICS; METABOLISM;

ALLOSTERIC REGULATION; ANTIGENS, CD13; BIOCATALYSIS; CISPLATIN; CYSTEINE; DIPEPTIDES; GLUTATHIONE; GLYCINE; HUMANS; KIDNEY DISEASES; KINETICS; MESNA; MODELS, BIOLOGICAL; PROTECTIVE AGENTS; RECOMBINANT PROTEINS;

EID: 79953774350     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1333-x     Document Type: Article

References (50)

1. Wong E, Giandomenico CM (1999) Current status of platinumbased antitumor drugs. Chem Rev 99:2451-2466
2. Gandara DR, Perez EA, Weibe V, De Gregorio MW (1991) Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Semin Oncol 18:49-55
3. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS (1977) The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39:1362-1371 (Pubitemid 8108286)
4. Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 213:551-556 (Pubitemid 10085160)
5. Kuhlmann MK, Burkhardt G, Kohler H (1997) Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 12:2478-2480 (Pubitemid 27520658)
6. Levi J, Jacobs C, Kalman SM, McTigue M, Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity: I. Effects of sulfhydryl groups in rat kidneys. J Pharmacol Exp Ther 213:545-550 (Pubitemid 10085159)
7. Tanaka H, Ishikawa E, Teshima S, Shimizu e (1986) Histopathological study of human cisplatin nephropathy. Toxicol Pathol 14:247-257 (Pubitemid 16016992)
8. Hausheer FH, Shanmugarajah D, Leverett BD, Chen X, Huang Q, Kochat H, Petluru PN, Parker AR (2010) Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase. Cancer Chemother Pharmacol 65:941-951
9. Jones MM, Basinger MA, Holscher MA (1992) Control of the nephrotoxicity of cisplatin by clinically used sulfur-containing compounds. Fundam Appl Toxicol 18:181-188
10. Gandara DR, Wiebe VJ, Perez EA, Makuch RW, DeGregorio MW (1990) Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hematol 10:353-365
11. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112 (Pubitemid 26230113)
12. Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, Petluru P, Zhao M, Murali D, Saxe JD, Yao S, Martinez N, Zukowski A, Rustum YM (1998) Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first-and second-generation protecting agents. Semin Oncol 25:584-599 (Pubitemid 28478065)
13. Anders MW, Dekant W (1998) Glutathione-dependent bioactivation of haloalkenes. Annu Rev Pharmacol Toxicol 38:501-537 (Pubitemid 28231504)
14. Schaeffer VH, Stevens JL (1987) The transport of S-cysteine conjugates in LLC-PK1 cells and its role in toxicity. Mol Pharmacol 31:506-512 (Pubitemid 17104372)
15. Stevens JL (1985) Isolation and characterization of a rat liver enzyme with both cysteine conjugate beta-lyase and kynureninase activity. J Biol Chem 260:7945-7950 (Pubitemid 15228233)
16. Wolfgang GH, Dominick MA, Walsh KM, Hoeschele JD, Pegg DG (1994) Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male Wistar rats. Fundam Appl Toxicol 22:73-79 (Pubitemid 24073659)
17. Dekant W, Henschler D (1999) Organ-specific carcinogenicity of haloalkenes mediated by glutathione conjugation. J Cancer Res Clin Oncol 125:174-181 (Pubitemid 29172508)
18. Hanigan MH, Gallagher BC, Taylor PT Jr, Large MK (1994) Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res 54:5925-5929
19. Hanigan MH, Gallagher BC, Taylor PT Jr (1996) Cisplatin nephrotoxicity: inhibition of gamma-glutamyl transpeptidase blocks the nephrotoxicity of cisplatin without reducing platinum concentrations in the kidney. Am J Obstet Gynecol 175:270-274 (Pubitemid 26390980)
20. Hanigan MH, Lykissa ED, Townsend DM, Ou CN, Barrios R, Lieberman MW (2001) Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. Am J Pathol 159:1889-1894 (Pubitemid 33062530)
21. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH (2003) Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14:1-10 (Pubitemid 36026291)
22. Wainford RD, Weaver RJ, Stewart KN, Brown P, Hawksworth GM (2008) Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology 249:184-193
23. Dekant W (2001) Chemical-induced nephrotoxicity mediated by glutathione S-conjugate formation. Toxicol Lett 124:21-36 (Pubitemid 33000346)
24. Pendyala L, Schwartz G, Smith P, Zdanowicz J, Murphy M, Hausheer F (2003) Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer Chemother Pharmacol 51:376-384 (Pubitemid 36649134)
25. Boven E, Hulscher S, Schluper H, Erkelens C, Pinedo H, van der Vijgh WJ (1998) Abstract 1078: BNP7787, a new protector of platinum-toxicities, does not inrfluence the antitumor efficacy of cisplatin or carboplatin. In: Proceedings of the AACR (89th Annual Meeting) vol 39, p 158
26. Boven E, Verschraagen M, Hulscher TM, Erkelens CA, Hausheer FH, Pinedo HM, van der Vijgh WJ (2002) BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer 38:1148-1156 (Pubitemid 34468022)
27. Boven E, Westerman M, van Groeningen CJ, Verschraagen M, Ruijter R, Zegers I, van der Vijgh WJ, Giaccone G (2005) Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule. Br J Cancer 92:1636-1643 (Pubitemid 40756473)
28. Hausheer FH, Rustum Y, Cao S, Haridas K, Reddy D, Seetharamalu P, Zhao M, Yao S, Pavankumar P, Murali D (1999) Abstract 1077: BNP7787: administration in vivo results in increased therapeutic index and toxicity reduction of platinum drugs. In: Proceedings of the AACR (89th Annual Meeting) vol 39, p 158
29. Hausheer FH, Kochat H, Parker AR, Ding D, Yao S, Hamilton SE, Petluru PN, Leverett BD, Bain SH, Saxe JD (2003) New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Cancer Chemother Pharmacol 52 (Suppl 1): S3-S15 (Pubitemid 37047018)
30. Verschraagen M, Kedde MA, Hausheer FH, van der Vijgh WJ (2003) The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG. Cancer Chemother Pharmacol 51:499-504 (Pubitemid 36791676)
31. Verschraagen M, Boven E, Torun E, Erkelens CA, Hausheer FH, van der Vijgh WJ (2004) Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats. Br J Cancer 90:1654-1659 (Pubitemid 38648252)
32. Verschraagen M, Boven E, Ruijter R, van der Born K, Berkhof J, Hausheer FH, van der Vijgh WJ (2003) Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites. Clin Pharmacol Ther 74:157-169 (Pubitemid 36951813)
33. Verschraagen M, Boven E, Torun E, Hausheer FH, Bast A, van der Vijgh WJ (2004) Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects. Biochem Pharmacol 68:493-502 (Pubitemid 38887431)
34. Verschraagen M, Bosma M, Zwiers TH, Torun E, van der Vijgh WJ (2003) Quantification of mesna and total mesna in kidney tissue by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci 783:33-42 (Pubitemid 35351630)
35. Verschraagen M, Zwiers TH, Torun E, Donker MG, Reinhoud NJ, van der Vijgh WJ (2003) Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector. J Pharm Sci 92:1040-1050 (Pubitemid 36523450)
36. Shanmugarajah D, Ding D, Huang Q, Chen X, Kochat H, Petluru PN, Ayala PY, Parker AR, Hausheer FH (2009) Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 877:857-866
37. Bauvois B, Dauzonne D (2006) Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev 26:88-130 (Pubitemid 43986471)
38. Kozak EM, Tate SS (1982) Glutathione-degrading enzymes of microvillus membranes. J Biol Chem 257:6322-6327 (Pubitemid 12029545)
39. Verschraagen M, Zwiers TH, de Koning PE, Welink J, van der Vijgh WJ (2001) Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 753:293-302 (Pubitemid 32217729)
40. Addlagatta A, Gay L, Matthews BW (2006) Structure of aminopeptidase N from Escherichia coli suggests a compartmentalized, gated active site. Proc Natl Acad Sci USA 103:13339-13344 (Pubitemid 44380109)
41. Daugaard G, Abildgaard U (1989) Cisplatin nephrotoxicity. A review. Cancer Chemother Pharmacol 25:1-9 (Pubitemid 20000790)
42. Townsend DM, Hanigan MH (2002) Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther 300:142-148 (Pubitemid 34028520)
43. Luan Y, Xu W (2007) The structure and main functions of aminopeptidase N. Curr Med Chem 14:639-647 (Pubitemid 46477717)
44. Hausheer F, Kanter P, Rustum Y, Cao S, Haridas K, Reddy D, Seetharamulu P, Zhao M, Yao S, Pavankumar P, Murali D (1997) Abstract 2089: BNP7787: a novel antitumor potentiating drug which protects against cisplatin and carboplatin toxicities. In: Proceedings of the AACR, (88th Annual Meeting) vol 38, p 311
45. Hausheer F, Cavaletti G, Tredici G., Oggioni N, Spinelli S, Pezzoni G, Manzotti C, Haridas K, Reddy D, Zhao M, Seetharamulu P, Yao S, Pavankumar P, Murali D, Wu M, Saxe J, Cavalletti e (1999) Abstract 2633: oral and intravenous BNP7787 protects against platinum neurotoxicity without in vitro or in vivo tumor protection. In: Proceedings of the AACR (90th Annual Meeting) vol 40, p 398
46. Hausheer FH, Kochat H, Zhao M, Seetharamulu P, Huang Q, Berghorn e (2001) Abstract 1990: BNP7787, a novel neuroprotective agent in taxane and platinum regimens, does not interfere with antitumor activity. In: Proceedings of the AACR (92nd Annual Meeting) vol 42, p 370
47. Verschraagen M, Boven E, Zegers I, Hausheer FH, van der Vijgh WJ (2003) Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report. Cancer Chemother Pharmacol 51:525-529 (Pubitemid 36791680)
48. Dekant W (1993) Bioactivation of nephrotoxins and renal carcinogens by glutathione S-conjugate formation. Toxicol Lett 67:151-160
49. Fournie-Zaluski MC, Coric P, Turcaud S, Bruetschy L, Lucas E, Noble F, Roques BP (1992) Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation. J Med Chem 35:1259-1266
50. Case DA, Pearlman DA, Caldwell JW, Cheatham III, TE, Ross WS, Simmerling CL, Darden TA, Merz KM, Stanton RV, Cheng AL, Vincent JJ, Crowley M, Tsui V, Radmer RJ, Duan Y, Pitera J, Massova I, Seibel GL, Singh UC, Weiner PK, Kollman PA (1999) Amber 6, University of California, San Francisco